Press
Releases

June 4, 2026 Jade Biosciences Announces Pricing of Public Offering of Common Stock June 3, 2026 Jade Biosciences Announces Proposed Underwritten Public Offering June 1, 2026 Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy May 29, 2026 Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy May 26, 2026 Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody May 26, 2026 Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy May 7, 2026 Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update April 23, 2026 Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 22, 2026 Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer March 6, 2026 Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update